Department of Gastroenterology, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China.
Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China.
World J Gastroenterol. 2019 Feb 28;25(8):955-966. doi: 10.3748/wjg.v25.i8.955.
Procyanidins have beneficial effects on metabolic syndrome and antimicrobial activity, but the mechanisms underlying these effects are unclear.
To investigate the effects of procyanidin B2 (PB2) on non-alcoholic fatty liver disease and to explore the possible mechanism.
Thirty male New Zealand white rabbits were randomized into three groups. All of them were fed either a high-fat-cholesterol diet (HCD) or chow diet. HCD-fed rabbits were treated with vehicle or PB2 daily for 12 wk. Body weight and food intake were evaluated once a week. Serum biomarkers, such as total cholesterols, triglycerides, and aspartate transaminase, were detected. All rabbits were sacrificed and histological parameters of liver were assessed by hematoxylin and eosin-stained sections. Moreover, several lipogenic genes and gut microbiota (by 16S rRNA sequencing) were investigated to explore the possible mechanism.
The HCD group had higher body weight, liver index, serum lipid profile, insulin resistance, serum glucose, and hepatic steatosis compared to the CHOW group. PB2 treatment prevented HCD-induced increases in body weight and hypertriglyceridemia in association with triglyceride accumulation in the liver. PB2 also ameliorated low-grade inflammation, which was reflected by serum lipopolysaccharides and improved insulin resistance. In rabbit liver, PB2 prevented the upregulation of steroid response element binding protein 1c and fatty acid synthase and the downregulation of carnitine palmitoyltransferase, compared to the HCD group. Moreover, HCD led to a decrease of in gut microbiota. PB2 significantly improved the proportions of at the phylum level and at the genus level.
Our results indicate the possible mechanism of PB2 to improve HCD-induced features of metabolic syndrome and provide a new dietary supplement.
原花青素对代谢综合征和抗菌活性有益，但这些作用的机制尚不清楚。
研究原花青素 B2 (PB2) 对非酒精性脂肪性肝病的影响，并探讨可能的机制。
30 只雄性新西兰白兔随机分为 3 组。所有动物均给予高脂肪高胆固醇饮食（HCD）或普通饮食。HCD 喂养的兔子每日给予载体或 PB2 治疗 12 周。每周评估一次体重和食物摄入量。检测血清生物标志物，如总胆固醇、甘油三酯和天冬氨酸转氨酶。所有兔子均被处死，通过苏木精-伊红染色切片评估肝脏组织学参数。此外，通过 16S rRNA 测序研究了几种脂肪生成基因和肠道微生物群，以探讨可能的机制。
与 CHOW 组相比，HCD 组的体重、肝脏指数、血清脂质谱、胰岛素抵抗、血清葡萄糖和肝脂肪变性均升高。PB2 治疗可预防 HCD 诱导的体重增加和高甘油三酯血症，并与肝脏甘油三酯堆积有关。PB2 还改善了低度炎症，表现为血清内毒素和改善了胰岛素抵抗。与 HCD 组相比，PB2 可预防固醇反应元件结合蛋白 1c 和脂肪酸合酶的上调以及肉碱棕榈酰转移酶的下调。此外，HCD 导致肠道微生物群减少。PB2 可显著改善门水平的 和属水平的 的比例。
我们的结果表明 PB2 改善 HCD 诱导的代谢综合征特征的可能机制，并提供了一种新的膳食补充剂。
